• Human APIs PowderRespiratory Drugs Raw Material Antiviral Antibacterial Antipyretic Analgesics Antihistamine Drugs Antineoplastic Cosmetic Raw Material
  • Pharmaceutical IntermediatesPharmaceutical intermediates Nutritional Supplements Pharmaceutical raw materials
  • OEM & ODMCapsule Softgel Capsule Gummies Drop & drinks Tables
  • Veterinary raw materialsAntibacterial anti-inflammatory Respiratory Drugs Anthelmintics Antiviral drugs Feed additives
  • About UsCompany profileQualificationQuality AssuranceService teamFactory TourR&D Center
  • Pharmaceutical intermediates Atazanavir Raw Materials Powder

    • Pharmaceutical intermediates Atazanavir Raw Materials Powder
    • Pharmaceutical intermediates Atazanavir Raw Materials Powder storehouse
    • Pharmaceutical intermediates Atazanavir Raw Materials Powder quality testing
    • Pharmaceutical intermediates Atazanavir Raw Materials Powder quality testing
    • Pharmaceutical intermediates Atazanavir Raw Materials Powder certificate

    Product Overview:

    Azanavir is a new type of HIV-1 protease inhibitor developed by Bristol-Myers Squibb. Azanavir sulfate was released in the United States on June 20, 2003 and in Europe on March 2, 2004 under the trade name Reyataz.

    Pharmaceutical intermediates Atazanavir Raw Materials Powder Attributes

    Atazanavir Raw Materials Powder

    CAS:198904-31-3

    MF:C38H52N6O7

    Atazanavir

    MW:704.86

    EINECS:812-543-8

    Specification: 99% min Atazanavir Powder

    Sample:Atazanavir

    Packaging:1kg/bag, 25kg/drum

    Brand: Henrikang

    Appearance:white

    Storage: Cool Dry Place

    Shelf Life: 2 Years

    Test Method: HPLC

    Pharmaceutical intermediates Atazanavir Raw Materials Powder Details

    Atazanavir Powder Usage and Synthesis.

    Azanavir is an inhibitor of azeptide HIV-1 protease. The product selectively inhibits the specific processing of viral Gag and GAG-pol polymers in HIV-1-infected cells, thereby blocking the formation of mature viruses. In vitro antiviral activity: The mean 50% inhibitory concentration (IC50) of azanavir against a large number of laboratory and clinical isolates of HIV-1 virus isolated from peripheral blood mononuclear cells, macrophages, CIM-SS cells, and MT2 cells without human serum was 2-5 nm.

    Atazanavir powder

    Pharmacological action of Atazanavir.

    This product is a novel azopeptidase protease inhibitor (PI). Its activity in vitro is not the same as that of non-peptide PIs such as Nelfinavir. This product is designed according to the X-ray diffraction study of enzym-azopeptidase complex and has a C-2 symmetric chemical structure. It is a highly selective and efficient inhibitor of HIV-1 protease, which inhibits the production of viral structural proteins, reverse transcriptase, integrase and protease by blocking the cleavage of viral gap and GAP-POL precursor polymerase, so that HIV-1-infected cells release non-infectious immature viral particles. This product has stronger inhibitory activity against multiple strains of HIV-1 virus than other PIs, and the median effective concentration (EC50) in vitro medium is 2.6 ~ 5.3nmol/L, and the 90% effective concentration (EC90) is 9 ~ 15nmol/L.

    Atazanavir

    In vitro study of Atazanavir.

    Atazanavir has effective activity against wild-type viruses in vitro with EC50 and EC90 of 2-5nM and 9-15nM, respectively. Atazanavir can effectively induce endoplasmic reticulum stress response in glioma cells, and the levels of GRP78 and CHOP are increased, and caspase-4 is activated, leading to cell death.

    Product method of Bulk Atazanavir Powder.

    Our advantage
    Our Factory
    Shipping
    Tel: 86-29-89601602
    WhatsApp: 8615091775531
    WeChat: 15091775531
    E-mail: sales21@interlgroup.com
    Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
    ©2023 Xi'an Henrikang Biotech Co., Ltd.,